Abstract
48
The majority of bacteraemias were community onset (70%); most were caused by Escherichia 
72
[4]; leading to enormous reliance on broad-spectrum agents [5] . The appropriateness of recommendations regarding aggressive empiric therapy with broad-spectrum antibiotics' [25] .
87
Two subsequent large, prospective studies have produced contrasting results among different 88 patient populations (26,27). However, <50% of cases had GNB bacteraemia in these studies. In a 89 retrospective study specifically in GNB bacteraemia Cain et al found an effect of empiric 90 antibiotic therapy only among patients with a high prior probability of death(28). 
RESULTS

151
Study sites achieved a median of 96.5% recruitment of eligible patients (IQR 93.5-100%) 152 obtaining prospective data on 679 adults with microbiologically confirmed GNB bacteraemia.
153
Nine (1%) who died on the day blood was taken for culture were excluded from primary 154 multivariable analyses, but included in sensitivity analyses. Data describing antimicrobial 155 susceptibility or treatment were missing for 54 (8%) patients, leaving 616 (91%) with complete 156 data on antibiotic treatment and 7-day mortality (figure 1). 30-day mortality data were missing 157 on a further five.
158
Overall mortality was 8% (52/679) and 15% (101/674) at 7 and 30-days respectively. Table 1   159 shows the univariable associations between mortality and patient and disease factors and 
172
Antibiotic resistance was most common to amoxicillin/ampicillin (64% for E. coli) and co-173 amoxiclav (36% overall). The most commonly used antibiotics were co-amoxiclav (32%) and 
200
In multivariable analysis adjusting for these inter-relationships, older age, higher NEWS score 201 and higher CRP independently predicted greater 7-day and 30-day mortality (Table 2) 
252
This contrast with the older literature may reflect advances in supportive care, changes in 253 patient mix and differences in the main antibiotic classes used.
254
Our study has limitations. We did not confirm antibiotic susceptibilities reported by diagnostic 255 laboratories. However, variation between sites would not be expected to obscure an impact of 256 antibiotic susceptibility across the whole study and should be small given that all the 257 laboratories participate in national quality assessments and are accredited by the Royal College 258 of Pathologists. A small number of patients were not recruited at some centres but there is no 259 reason to think these were selected or will bias our findings. We used mortality as our primary 
